Page 63 -
P. 63

Notes to the Consolidated Financial Statements


                                                                                                 31st March 2017


             2    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)


                  2.8  Intangible assets (Continued)

                      (b)  Deferred development costs

                           Research  expenditure  is  recognised  as  an  expense  as  incurred.  Costs  incurred  on
                           development  projects  (directly  attributable  to  the  design  and  testing  of  new  or  improved
                           products) are recognised as intangible assets when the following criteria are fulfilled:


                           (i)   it is technically feasible to complete the developing/developed product so that it will be
                                available for use or sale;


                           (ii)   management intends to complete the developing/developed product and use or sell it;

                           (iii)  there is an ability to use or sell the developing/developed product;


                           (iv)  it can be demonstrated how the developing/developed product will generate probable
                                future economic benefits;

                           (v)   adequate technical, financial and other resources to complete the development and to
                                use or sell the developing/developed product are available; and

                           (vi)  the  expenditure  attributable  to  the  developing/developed  product  during  its
                                development can be reliably measured.


                       Other development expenditures that do not meet these criteria are recognised as expenses as
                       incurred. Development costs previously recognised as an expense are not recognised as an asset
                       in  a  subsequent  period.  Capitalised  development  costs  are  recorded  as  intangible  assets  and
                       amortised over a period of 36 months to reflect the pattern in which the relevant economic benefits
                       are recognised. Development assets are tested for impairment annually, in accordance with HKAS
                       36.


                  2.9  Impairment of non-financial assets

                       Assets  that  have  an  indefinite  useful  life  are  not  subject  to  amortisation  and  are  tested  annually
                       for  impairment.  Assets  that  are  subject  to  amortisation  are  reviewed  for  impairment  whenever
                       events  or  changes  in  circumstances  indicate  that  the  carrying  amount  may  not  be  recoverable.
                       An impairment loss is recognised for the amount by which the asset’s carrying amount exceeds
                       its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to
                       sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest
                       levels for which there are separately identifiable cash flows (cash-generating units). Non-financial
                       assets  other  than  goodwill  that  suffered  an  impairment  are  reviewed  for  possible  reversal  of  the
                       impairment at each reporting date.






                                                                      ALCO HOLDINGS LIMITED  ANNUAL REPORT 2017  61
   58   59   60   61   62   63   64   65   66   67   68